Eravacycline: A New Treatment Option for Complicated Intra-Abdominal Infections in the Age of Multidrug Resistance

References

• European Centre for Disease Prevention and Control . Antimicrobial resistance. https://www.ecdc.europa.eu/en/antimicrobial-resistance
   Google Scholar
• Infectious Diseases Society of America . Antimicrobial resistance: a public health crisis (2016).
   Google Scholar
• Centers for Disease Control and Prevention . Antibiotic resistance threats in the United States (2013). https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
   Google Scholar
• World Health Organization . Antimicrobial resistance (2018). https://www.who.int/antimicrobial-resistance/en/
   Google Scholar
• Chong Y , ShimodaS, ShimonoN. Current epidemiology, genetic evolution and clinical impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect. Genet. Evol.61, 185–188 (2018).
   PubMed Web of Science ®Google Scholar
• Schwaber MJ , CarmeliY. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother.60(5), 913–920 (2007).
   PubMed Web of Science ®Google Scholar
• Thabit AK , CrandonJL, NicolauDP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin. Pharmacother.16(2), 159–177 (2015).
   PubMed Web of Science ®Google Scholar
• Girometti N , LewisRE, GiannellaMet al. Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine93(17), 298–309 (2014).
   PubMed Web of Science ®Google Scholar
• Frere JM , SauvageE, KerffF. From ‘an enzyme able to destroy penicillin’ to carbapenemases: 70 years of β-lactamase misbehaviour. Curr. Drug Targets17(9), 974–982 (2016).
   PubMed Web of Science ®Google Scholar
• Harris P TP , DavidLye D, MoY. The MERINO trial: piperacillin-tazobactam versus meropenem for the definitive treatment of bloodstream infections caused by third-generation cephalosporin nonsusceptible Escherichia coli or Klebsiella spp.: an international multi-centre open label non-inferiority randomised controlled trial. Presented at: European Congress of Clinical Microbiology and Infectious Diseases. Madrid, Spain, 21–24 April 2018.
   Google Scholar
• Logan LK , WeinsteinRA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J. Infect. Dis.215(Suppl. 1), S28–S36 (2017).
   PubMedGoogle Scholar
• Molton JS , TambyahPA, AngBS, LingML, FisherDA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin. Infect. Dis.56(9), 1310–1318 (2013).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J , Gutierrez-GutierrezB, MachucaI, PascualA. Treatment of infections caused by extended-spectrum-β-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Rev.31(2), pii:e00079-17 (2018).
   Web of Science ®Google Scholar
• Eljaaly K , AlharbiA, AlshehriS, OrtwineJK, PogueJM. Plazomicin: a novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections. Drugs79(3), 243–269 (2019).
   PubMed Web of Science ®Google Scholar
• Peri AM , DoiY, PotoskiBA, HarrisPNA, PatersonDL, RighiE. Antimicrobial treatment challenges in the era of carbapenem resistance. Diagn. Microbiol. Infect. Dis.94(4), 413–425 (2019).
   PubMed Web of Science ®Google Scholar
• Petty LA , HenigO, PatelTS, PogueJM, KayeKS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect. Drug Resist.11, 1461–1472 (2018).
   PubMed Web of Science ®Google Scholar
• Sheu CC , ChangYT, LinSY, ChenYH, HsuehPR. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front. Microbiol.10, 80 (2019).
   PubMed Web of Science ®Google Scholar
• Manenzhe RI , ZarHJ, NicolMP, KabaM. The spread of carbapenemase-producing bacteria in Africa: a systematic review. J. Antimicrob. Chemother.70(1), 23–40 (2015).
   PubMed Web of Science ®Google Scholar
• Surveillance of antimicrobial resistance in Europe – annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017. In: Antimicrobial Resistance Surveillance in Europe. European Centre for Disease Prevention and Control, Stockholm, Sweden (2018).
   Google Scholar
• Lob SH , BiedenbachDJ, BadalRE, KazmierczakKM, SahmDF. Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011–2013. J. Global Antimicrob. Resist.3(3), 190–197 (2015).
   PubMed Web of Science ®Google Scholar
• McDanel J , SchweizerM, CrabbVet al. Incidence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella infections in the United States: a systematic literature review. Infect. Control Hosp. Epidemiol.38(10), 1209–1215 (2017).
   PubMed Web of Science ®Google Scholar
• Jean SS , HsuehPR. Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008–14: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). J. Antimicrob. Chemother.72(1), 166–171 (2017).
   PubMed Web of Science ®Google Scholar
• Mazuski JE , SolomkinJS. Intra-abdominal infections. Surg. Clin. North Am.89(2), 421–437 (2009).
   PubMed Web of Science ®Google Scholar
• Edelsberg J , BergerA, SchellS, MallickR, KuznikA, OsterG. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg. Infect.9(3), 335–347 (2008).
   PubMed Web of Science ®Google Scholar
• Tellado JM , SenSS, CalotoMT, KumarRN, NoceaG. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain. Scandinavian J. Infect. Dis.39(11–12), 947–955 (2007).
   PubMed Web of Science ®Google Scholar
• Chong YP , BaeIG, LeeSRet al. Clinical and economic consequences of failure of initial antibiotic therapy for patients with community-onset complicated intra-abdominal infections. PLoS ONE10(4), e0119956 (2015).
   PubMed Web of Science ®Google Scholar
• Mazuski JE , TessierJM, MayAKet al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg. Infect.18(1), 1–76 (2017).
   PubMed Web of Science ®Google Scholar
• Solomkin JS , MazuskiJE, BradleyJSet al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin. Infect. Dis.50(2), 133–164 (2010).
   PubMed Web of Science ®Google Scholar
• Sartelli M , Chichom-MefireA, LabricciosaFMet al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J. Emerg. Surg.12, 29 (2017).
   PubMed Web of Science ®Google Scholar
• Allegranzi B , BischoffP, de JongeSet al. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect. Dis.16(12), e276–e287 (2016).
   PubMedGoogle Scholar
• Berrios-Torres SI , UmscheidCA, BratzlerDWet al. Centers for Disease Control and Prevention Guideline for the prevention of surgical site infection, 2017. JAMA Surg.152(8), 784–791 (2017).
   PubMed Web of Science ®Google Scholar
• Edelsberg J , BergerA, WeberDJ, MallickR, KuznikA, OsterG. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect. Control Hosp. Epidemiol.29(2), 160–169 (2008).
   PubMed Web of Science ®Google Scholar
• Bartlett JG , OnderdonkAB, LouieT, KasperDL, GorbachSL. A review. Lessons from an animal model of intra-abdominal sepsis. Arch. Surg.113(7), 853–857 (1978).
   PubMedGoogle Scholar
• Stevens DL , BryantAE. Necrotizing soft-tissue infections. N. Engl. J. Med.377(23), 2253–2265 (2017).
   PubMed Web of Science ®Google Scholar
• Bohnen JM , MarshallJC, FryDE, JohnsonSB, SolomkinJS. Clinical and scientific importance of source control in abdominal infections: summary of a symposium. Can. J. Surg.42(2), 122–126 (1999).
   PubMed Web of Science ®Google Scholar
• Schein M , MarshallJ. Source control for surgical infections. World J. Surg.28(7), 638–645 (2004).
   PubMed Web of Science ®Google Scholar
• Heseltine PN , YellinAE, ApplemanMDet al. Perforated and gangrenous appendicitis: an analysis of antibiotic failures. J. Infect. Dis.148(2), 322–329 (1983).
   PubMed Web of Science ®Google Scholar
• Yellin AE , HeseltinePN, BerneTVet al. The role of Pseudomonas species in patients treated with ampicillin and Sulbactam for gangrenous and perforated appendicitis. Surg. Ggynecol. Obstet.161(4), 303–307 (1985).
   PubMedGoogle Scholar
• Andersen BR , KallehaveFL, AndersenHK. Antibiotics versus placebo for prevention of postoperative infection after appendicectomy. Cochrane Database Syst. Rev. (3), Cd001439 (2005).
   PubMed Web of Science ®Google Scholar
• Snydman DR , McDermottLA, JacobusNV, KersteinK, GrossmanTH, SutcliffeJA. Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob. Agents Chemother.62(5), pii:e02206-17 (2018).
   Web of Science ®Google Scholar
• Zhanel GG , BaxterMR, AdamHJ, SutcliffeJ, KarlowskyJA. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015. Diagn. Microbiol. Infect. Dis.91(1), 55–62 (2018).
   PubMed Web of Science ®Google Scholar
• Livermore DM , MushtaqS, WarnerM, WoodfordN. Invitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob. Agents Chemother.60(6), 3840–3844 (2016).
   PubMed Web of Science ®Google Scholar
• van Harten RM , WillemsRJL, MartinNI, HendrickxAPA. Multidrug-resistant enterococcal infections: new compounds, novel antimicrobial therapies?Trends Microbiol.25(6), 467–479 (2017).
   PubMed Web of Science ®Google Scholar
• Goldstein EJC , CitronDM, TyrrellKL. In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species. Anaerobe52, 122–124 (2018).
   PubMed Web of Science ®Google Scholar
• Seifert H , StefanikD, SutcliffeJA, HigginsPG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int. J. Antimicrob. Agents51(1), 62–64 (2018).
   PubMed Web of Science ®Google Scholar
• Grossman TH , StarostaAL, FyfeCet al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob. Agents Chemother.56(5), 2559–2564 (2012).
   PubMed Web of Science ®Google Scholar
• Abdallah M , OlafisoyeO, CortesC, UrbanC, LandmanD, QualeJ. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob. Agents Chemother.59(3), 1802–1805 (2015).
   PubMed Web of Science ®Google Scholar
• Zhang Y , LinX, BushK. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J. Antibiot.69(8), 600–604 (2016).
   PubMed Web of Science ®Google Scholar
• Zhang F , BaiB, XuGJet al. Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance. BMC Microbiol.18(1), 211 (2018).
   PubMedGoogle Scholar
• Solomkin J , HershbergerE, MillerBet al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, Phase III trial (ASPECT-cIAI). Clin. Infect. Dis.60(10), 1462–1471 (2015).
   PubMed Web of Science ®Google Scholar
• Mazuski JE , GasinkLB, ArmstrongJet al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, Phase III program. Clin. Infect. Dis.62(11), 1380–1389 (2016).
   PubMed Web of Science ®Google Scholar
• Solomkin JS , RameshMK, CesnauskasGet al. Phase II, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob. Agents Chemother.58(4), 1847–1854 (2014).
   PubMed Web of Science ®Google Scholar
• Solomkin J , EvansD, SlepaviciusAet al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg.152(3), 224–232 (2017).
   PubMed Web of Science ®Google Scholar
• Newman JV , ZhouJ, IzmailyanS, TsaiL. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob. Agents Chemother.62(11), pii:e01174-18 (2018).
   Web of Science ®Google Scholar
• Meagher AK , AmbrosePG, GraselaTH, Ellis-GrosseEJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis.41(Suppl. 5), S333–S340 (2005).
   PubMed Web of Science ®Google Scholar
• Babinchak T , Ellis-GrosseE, DartoisN, RoseGM, LohE. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis.41(Suppl. 5), S354–S367 (2005).
   PubMed Web of Science ®Google Scholar
• Lauf L , OzsvarZ, MithaIet al. Phase III study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn. Microbiol. Infect. Dis.78(4), 469–480 (2014).
   PubMed Web of Science ®Google Scholar
• Matthews P , AlpertM, RahavGet al. A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections. BMC Infect. Dis.12, 297 (2012).
   PubMed Web of Science ®Google Scholar
• O’Riordan W , MehraP, ManosP, KingsleyJ, LawrenceL, CammarataS. A randomized Phase II study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int. J. Infect. Dis.30, 67–73 (2015).
   PubMed Web of Science ®Google Scholar
• Towfigh S , PasternakJ, PoirierA, LeisterH, BabinchakT. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin. Microbiol. Infect.16(8), 1274–1281 (2010).
   PubMed Web of Science ®Google Scholar
• Harris PNA , TambyahPA, LyeDCet al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA320(10), 984–994 (2018).
   PubMed Web of Science ®Google Scholar
• Vardakas KZ , TansarliGS, RafailidisPI, FalagasME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J. Antimicrob. Chemother.67(12), 2793–2803 (2012).
   PubMed Web of Science ®Google Scholar
• Tamma PD , HanJH, RockCet al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin. Infect. Dis.60(9), 1319–1325 (2015).
   PubMed Web of Science ®Google Scholar
• McLaughlin M , AdvinculaMR, MalczynskiM, QiC, BolonM, ScheetzMH. Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. Antimicrob. Agents Chemother.57(10), 5131–5133 (2013).
   PubMed Web of Science ®Google Scholar
• Willyard C . The drug-resistant bacteria that pose the greatest health threats. Nature543(7643), 15 (2017).
   PubMed Web of Science ®Google Scholar
• Kelly AM , MathemaB, LarsonEL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. Int. J. Antimicrob. Agents50(2), 127–134 (2017).
   PubMed Web of Science ®Google Scholar
• Bush K . Game changers: new β-lactamase inhibitor combinations targeting antibiotic resistance in Gram-negative bacteria. ACS Infect. Dis.4(2), 84–87 (2018).
   PubMed Web of Science ®Google Scholar
• Pogue JM , BonomoRA, KayeKS. Ceftazidime/avibactam, meropenem/vaborbactam or both? Clinical and formulary considerations. Clin. Infect. Dis.68(3), 519–524 (2018).
   Web of Science ®Google Scholar
• Wright H , BonomoRA, PatersonDL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?Clin. Microbiol. Infect.23(10), 704–712 (2017).
   PubMed Web of Science ®Google Scholar
• Nelson K , HemarajataP, SunDet al. Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob. Agents Chemother.61(10), pii:e00989-17 (2017).
   Web of Science ®Google Scholar
• Rex JH , TalbotGH, GoldbergerMJet al. Progress in the fight against multidrug-resistant bacteria 2005–2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clin. Infect. Dis.65(1), 141–146 (2017).
   PubMed Web of Science ®Google Scholar
• Boucher HW , AmbrosePG, ChambersHFet al. White paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs. J. Infect. Dis.216(2), 228–236 (2017).
   PubMed Web of Science ®Google Scholar
• Wunderink RG , Giamarellos-BourboulisEJ, RahavGet al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect. Dis. Ther.7(4), 439–455 (2018).
   PubMed Web of Science ®Google Scholar
• Ben-David D , KordevaniR, KellerNet al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin. Microbiol. Infect.18(1), 54–60 (2012).
   PubMed Web of Science ®Google Scholar
• Dubinsky-Pertzov B , TemkinE, HarbarthSet al. Carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae and the risk of surgical site infection after colorectal surgery: a prospective cohort study. Clin. Infect. Dis.68(10), 1699–1704 (2018).
   Web of Science ®Google Scholar
• US FDA . Guidance for industry: complicated intra-abdominal infections: developing drugs for treatment (2018). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/complicated-intra-abdominal-infections-developing-drugs-treatment
   Google Scholar
• Solomkin JS , YellinAE, RotsteinODet al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative Phase III trial. Ann. Surg.237(2), 235–245 (2003).
   PubMed Web of Science ®Google Scholar
• Malangoni MA , SongJ, HerringtonJ, ChoudhriS, PertelP. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann. Surg.244(2), 204–211 (2006).
   PubMed Web of Science ®Google Scholar
• Wong D , SpellbergB. Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant Enterobacteriaceae. Virulence8(4), 383–390 (2017).
   PubMed Web of Science ®Google Scholar
• Wilson APR . Sparing carbapenem usage. J. Antimicrob. Chemother.72(9), 2410–2417 (2017).
   PubMed Web of Science ®Google Scholar